• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Trends in Post-Kala-Azar Dermal Leishmaniasis in Sudan: Cases, Ethnic Distribution, and Recovery.苏丹黑热病后皮肤利什曼病的趋势:病例、种族分布及康复情况
Am J Trop Med Hyg. 2025 Mar 18;112(6):1196-1200. doi: 10.4269/ajtmh.24-0602. Print 2025 Jun 4.
2
A clinico-epidemiological study, assessing possible predictors of mortality and health-related quality of life for people living with visceral leishmaniasis - human immune virus (VL-HIV) co-infection in a high burden kala-azar endemic state of India: a descriptive cross-sectional study.一项临床流行病学研究,评估印度黑热病高负担流行地区内脏利什曼病与人类免疫病毒(VL-HIV)合并感染患者的死亡率及健康相关生活质量的可能预测因素:一项描述性横断面研究。
BMC Infect Dis. 2025 Jul 2;25(1):887. doi: 10.1186/s12879-025-10768-y.
3
Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India.印度阿苯达唑治疗内脏利什曼病后皮肤利什曼病。
Am J Trop Med Hyg. 2024 Jun 4;111(1):59-63. doi: 10.4269/ajtmh.23-0738. Print 2024 Jul 3.
4
Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.苏丹东部的地方性黑热病:黑热病后皮肤利什曼病
Am J Trop Med Hyg. 1995 Apr;52(4):299-305. doi: 10.4269/ajtmh.1995.52.299.
5
Interventions for Old World cutaneous leishmaniasis.旧世界皮肤利什曼病的干预措施。
Cochrane Database Syst Rev. 2017 Dec 1;12(12):CD005067. doi: 10.1002/14651858.CD005067.pub5.
6
Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.苏丹的黑热病后皮肤利什曼病:临床表现与鉴别诊断
Br J Dermatol. 2000 Jul;143(1):136-43. doi: 10.1046/j.1365-2133.2000.03603.x.
7
Treatment Outcomes of Single-Dose Liposomal Amphotericin B-Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India.印度比哈尔邦单剂量脂质体两性霉素B治疗内脏利什曼病患者的治疗结果及影响疗效的因素
Am J Trop Med Hyg. 2024 Oct 8;111(6):1198-1205. doi: 10.4269/ajtmh.23-0640. Print 2024 Dec 4.
8
Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.印度晚期内脏利什曼病后皮肤利什曼病(PKDL)临床流行病学变化:在四个流行地区的调查结果。
J Vector Borne Dis. 2020 Apr-Jun;57(2):161-169. doi: 10.4103/0972-9062.310875.
9
Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).脂质体两性霉素B(安必素)治疗黑热病后皮肤利什曼病(PKDL)的疗效。
Ann Trop Med Parasitol. 2005 Sep;99(6):563-9. doi: 10.1179/136485905X514127.
10
Interventions for Old World cutaneous leishmaniasis.旧世界皮肤利什曼病的干预措施。
Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067. doi: 10.1002/14651858.CD005067.pub4.

本文引用的文献

1
The potential impact of human visceral leishmaniasis vaccines on population incidence.人体内脏利什曼病疫苗对人群发病率的潜在影响。
PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008468. doi: 10.1371/journal.pntd.0008468. eCollection 2020 Jul.
2
Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.定量评估卡拉巴肿后皮肤利什曼病对沙蝇的感染性。
Clin Infect Dis. 2019 Jul 2;69(2):251-258. doi: 10.1093/cid/ciy891.
3
Epidemiology of visceral leishmaniasis among children in Gadarif hospital, eastern Sudan.苏丹东部加达里夫医院儿童内脏利什曼病的流行病学
BMC Public Health. 2016 Dec 7;16(1):1234. doi: 10.1186/s12889-016-3875-2.
4
Elimination of visceral leishmaniasis on the Indian subcontinent.印度次大陆内脏利什曼病的消除
Lancet Infect Dis. 2016 Dec;16(12):e304-e309. doi: 10.1016/S1473-3099(16)30140-2. Epub 2016 Sep 28.
5
Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.在苏丹东部常规条件下使用葡糖酸锑钠和巴龙霉素治疗内脏利什曼病
Trop Med Int Health. 2015 Dec;20(12):1674-84. doi: 10.1111/tmi.12603. Epub 2015 Nov 11.
6
Post kala-azar dermal leishmaniasis: an unresolved mystery.内脏利什曼病后皮肤利什曼病:一个悬而未决的谜。
Trends Parasitol. 2014 Feb;30(2):65-74. doi: 10.1016/j.pt.2013.12.004. Epub 2014 Jan 2.
7
Leishmaniasis: clinical syndromes and treatment.利什曼病:临床综合征与治疗。
QJM. 2014 Jan;107(1):7-14. doi: 10.1093/qjmed/hct116. Epub 2013 Jun 5.
8
Development of Leishmania vaccines: predicting the future from past and present experience.利什曼原虫疫苗的研发:从过去和现在的经验预测未来
J Biomed Res. 2013 Mar;27(2):85-102. doi: 10.7555/JBR.27.20120064. Epub 2012 Sep 30.
9
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.东非地区内脏利什曼病对巴龙霉素反应的地理差异:一项多中心、开放标签、随机试验。
PLoS Negl Trop Dis. 2010 Oct 26;4(10):e709. doi: 10.1371/journal.pntd.0000709.
10
The relationship between leishmaniasis and AIDS: the second 10 years.利什曼病与艾滋病的关系:第二个十年
Clin Microbiol Rev. 2008 Apr;21(2):334-59, table of contents. doi: 10.1128/CMR.00061-07.

苏丹黑热病后皮肤利什曼病的趋势:病例、种族分布及康复情况

Trends in Post-Kala-Azar Dermal Leishmaniasis in Sudan: Cases, Ethnic Distribution, and Recovery.

作者信息

Osman Osama S, Hamid Mohamed E

机构信息

Gadarif Regional Institute of Endemic Diseases, University of Gadarif, Gadarif, Sudan.

Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia.

出版信息

Am J Trop Med Hyg. 2025 Mar 18;112(6):1196-1200. doi: 10.4269/ajtmh.24-0602. Print 2025 Jun 4.

DOI:10.4269/ajtmh.24-0602
PMID:40101288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12139568/
Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease that can develop after treatment of leishmaniasis. It causes significant health risks and serves as a reservoir, perpetuating transmission. Current information on PKDL characteristics is crucial for effective disease management and control. This study aimed to describe clinical and epidemiological characteristics of PKDL patients in eastern Sudan. A retrospective cross-sectional study was conducted on suspected PKDL patients (N = 37) at a tertiary hospital in eastern Sudan. Blood samples were tested for anti-rK39 antibodies to confirm the diagnosis of the disease. Demographic, clinical, and epidemiological data of the PKDL patients were gathered and analyzed. Most PKDL cases (69.4%) came from specific locations involving one ethnic group (94.6%), mainly affecting young males (54.1%). A family history of PKDL was noted in only 27.0% of cases; 51.4% developed PKDL within 1 month after visceral leishmaniasis (VL) treatment. Most cases (56.8%) were grade 1 (a low level of parasitic load), predominantly featuring macular (51.4%), papular (18.9%), and nodular (13.5%) lesions. All patients had skin rashes; 91.9% exhibited no fever, and 29.7% reported itching. Lesions appeared within a month after VL treatment, with most patients recovering spontaneously within 3-18 months. PKDL was particularly prevalent in specific regions and ethnic groups, namely the Masaleet and Dago tribes. These findings can enhance PKDL understanding and management in the region.

摘要

黑热病后皮肤利什曼病(PKDL)是一种被忽视的热带疾病,可在利什曼病治疗后发生。它会带来重大健康风险,并作为传染源,使疾病传播持续存在。目前关于PKDL特征的信息对于有效管理和控制该疾病至关重要。本研究旨在描述苏丹东部PKDL患者的临床和流行病学特征。对苏丹东部一家三级医院的疑似PKDL患者(N = 37)进行了一项回顾性横断面研究。检测血样中的抗rK39抗体以确诊该疾病。收集并分析了PKDL患者的人口统计学、临床和流行病学数据。大多数PKDL病例(69.4%)来自涉及一个民族(94.6%)的特定地点,主要影响年轻男性(54.1%)。仅27.0%的病例有PKDL家族史;51.4%在内脏利什曼病(VL)治疗后1个月内出现PKDL。大多数病例(56.8%)为1级(寄生虫载量低),主要表现为斑疹(51.4%)、丘疹(18.9%)和结节(13.5%)病变。所有患者均有皮疹;91.9%无发热,29.7%有瘙痒症状。病变在VL治疗后1个月内出现,大多数患者在3 - 18个月内自发康复。PKDL在特定地区和民族中尤为普遍,即马萨利特部落和达戈部落。这些发现可增进对该地区PKDL的了解和管理。